On May 6, 2021, Amplitude Healthcare Corporation (Nasdaq: AMHC), a special purpose acquisition company sponsored by affiliates of Avego Management, LLC and Metalmark Capital, announced that it had entered into a business combination agreement with Jasper Therapeutics, Inc., a biotechnology company focused on hematopoietic cell transplant therapies.  Concurrently with execution of the business combination agreement, Amplitude entered into subscription agreements with investors for a $100 million committed PIPE financing, led by investors Federated Hermes Kaufmann Funds, Amgen, Apeiron Investment Group, Avego, Velan Capital, Metalmark, Kingdon Capital Management, Woodline Partners LP, Abingworth LLP, Qiming Venture Partners USA, Surveyor Capital (a Citadel company), Roche Venture Fund and Alexandria Venture Investments, LLC. 

Upon closing of the transaction, the combined company is expected to be listed on Nasdaq under the new ticker symbol "JSPR," and the company is expected to have an initial market capitalization of approximately $490 million. The transaction is subject to customary closing conditions and is expected to close in the third quarter of 2021.

WilmerHale is representing Amplitude in the deal, with a team led by partners Chris Barnstable-Brown and Glenn Pollner, which also included counsel Chip McCorkle, senior associate Victoria Peluso and associate J.P. Mohler on corporate matters, and partners Ciara Baker, Scott Kilgore, Julie Hogan Rodgers, Ariel Soiffer, Bruce Manheim, Hartmut Schneider, and Jason Chipman, senior attorney Edward Sharon, senior associate Ben Kelsey, and associates Lauren Roberts and Chris Shin on equity compensation, tax, employee benefits, intellectual property, antitrust and regulatory matters.